Pub Date : 2023-04-26DOI: 10.4274/tji.galenos.2023.29491
A. Mahapatra, H. Verma, Sagorika Nag, Santosh Singh, A. Khattri, L. Bhaskar
{"title":"Advances in the Molecular Etiology of Severe Combined Immunodeficiency and Its Screening","authors":"A. Mahapatra, H. Verma, Sagorika Nag, Santosh Singh, A. Khattri, L. Bhaskar","doi":"10.4274/tji.galenos.2023.29491","DOIUrl":"https://doi.org/10.4274/tji.galenos.2023.29491","url":null,"abstract":"","PeriodicalId":41088,"journal":{"name":"Turkish Journal of Immunology","volume":"23 1","pages":""},"PeriodicalIF":1.2,"publicationDate":"2023-04-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89952551","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-12-29DOI: 10.4274/tji.galenos.2022.54154
Mehri Joghataei, G. Pouladfar, F. Shahidi, M. Kalani
{"title":"Evaluating the Effect of a Food-origin Lactobacillus plantarum Strain on Th17 Related Cytokines","authors":"Mehri Joghataei, G. Pouladfar, F. Shahidi, M. Kalani","doi":"10.4274/tji.galenos.2022.54154","DOIUrl":"https://doi.org/10.4274/tji.galenos.2022.54154","url":null,"abstract":"","PeriodicalId":41088,"journal":{"name":"Turkish Journal of Immunology","volume":"74 1","pages":""},"PeriodicalIF":1.2,"publicationDate":"2022-12-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79976762","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-12-29DOI: 10.4274/tji.galenos.2022.63497
Sumi Priyadarshini, D. Appukuttan, D. Victor, Santhosh Venkadassalapathy, V. Naik
{"title":"Expression of NLRC4 Inflammasome and Its Correlation with Treponema denticola in Stage III/IV Periodontitis with Type II Diabetes Mellitus","authors":"Sumi Priyadarshini, D. Appukuttan, D. Victor, Santhosh Venkadassalapathy, V. Naik","doi":"10.4274/tji.galenos.2022.63497","DOIUrl":"https://doi.org/10.4274/tji.galenos.2022.63497","url":null,"abstract":"","PeriodicalId":41088,"journal":{"name":"Turkish Journal of Immunology","volume":"12 1","pages":""},"PeriodicalIF":1.2,"publicationDate":"2022-12-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80931390","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-12-29DOI: 10.4274/tji.galenos.2022.55264
S. Khatib
The basic concept of vaccination has been based on engendering an adaptive immune response armed with effective immune cells, memory cells, and cytokines. These elements cooperate to mount either a humoral or a cell-mediated response. Coronavirus disease-2019 vaccines, although diversified, adapted the same objective with the previous vaccines prepared since Edward Jenner's work. The spike surface protein (S) and the receptor binding domain constituted the main antigenic determinants for which the binding antibodies as well as the neutralizing antibodies were secreted. The unprecedented use of mRNA vaccines represented an unmatched breakthrough, which paved the road for a new era of vaccine generation. They showed a substantial ability to elicit antibody secretion with a moderate helper T cell response just after inoculation of the first dose. Besides, the adenoviruses-shuttled vaccines were able to engender a spectrum of polyclonal antibodies including neutralizing antibodies apt to drive a multitude of antibodies-mediated functions and activate T cell immune responses. In either case, the antibody titers as well as lymphocytes-mediated responses were significantly intensified. Deciphering the mechanisms of immune response activation by the inoculated vaccines in addition to the elaboration of innate elements involvement should open the door for a better decryption of the induced immune protection and pave the road for the formulation of a more effective vaccine that surmounts the incessant mutational variation of the viral antigenic attributes. (English) [ FROM AUTHOR]
{"title":"The Rationale Behind the Effectiveness of COVID-19 Vaccines and Associated Immunological Mechanisms","authors":"S. Khatib","doi":"10.4274/tji.galenos.2022.55264","DOIUrl":"https://doi.org/10.4274/tji.galenos.2022.55264","url":null,"abstract":"The basic concept of vaccination has been based on engendering an adaptive immune response armed with effective immune cells, memory cells, and cytokines. These elements cooperate to mount either a humoral or a cell-mediated response. Coronavirus disease-2019 vaccines, although diversified, adapted the same objective with the previous vaccines prepared since Edward Jenner's work. The spike surface protein (S) and the receptor binding domain constituted the main antigenic determinants for which the binding antibodies as well as the neutralizing antibodies were secreted. The unprecedented use of mRNA vaccines represented an unmatched breakthrough, which paved the road for a new era of vaccine generation. They showed a substantial ability to elicit antibody secretion with a moderate helper T cell response just after inoculation of the first dose. Besides, the adenoviruses-shuttled vaccines were able to engender a spectrum of polyclonal antibodies including neutralizing antibodies apt to drive a multitude of antibodies-mediated functions and activate T cell immune responses. In either case, the antibody titers as well as lymphocytes-mediated responses were significantly intensified. Deciphering the mechanisms of immune response activation by the inoculated vaccines in addition to the elaboration of innate elements involvement should open the door for a better decryption of the induced immune protection and pave the road for the formulation of a more effective vaccine that surmounts the incessant mutational variation of the viral antigenic attributes. (English) [ FROM AUTHOR]","PeriodicalId":41088,"journal":{"name":"Turkish Journal of Immunology","volume":"18 1","pages":""},"PeriodicalIF":1.2,"publicationDate":"2022-12-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84609851","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-12-29DOI: 10.4274/tji.galenos.2022.83803
G. Aslan, Gamze Yapıcı
{"title":"Tuberculosis Immunology; the Ambivalence of the Ancient Disease Continues to Amaze","authors":"G. Aslan, Gamze Yapıcı","doi":"10.4274/tji.galenos.2022.83803","DOIUrl":"https://doi.org/10.4274/tji.galenos.2022.83803","url":null,"abstract":"","PeriodicalId":41088,"journal":{"name":"Turkish Journal of Immunology","volume":"26 1","pages":""},"PeriodicalIF":1.2,"publicationDate":"2022-12-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77933913","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-12-29DOI: 10.4274/tji.galenos.2022.70298
Demet GÜR VURAL, Büşra Usta, Muhammet Samet Emre Daştan, Y. Tanrıverdi Çaycı, K. Bilgin, H. Bilek, A. Birinci
Objective: Coronavirus disease-2019 (COVID-19) pandemic caused by the severe acute respiratory syndrome-coronavirus-2 continues across the world. Some patients with COVID-19 develop cytokine storm secondary to virally driven hyper-inflammation. This study aimed to assess the relationship of interleukin-6 (IL-6), procalsitonin (PCT) and C-reactive protein (CRP) levels with the severity of the disease in patients with COVID-19. Materials and Methods: This retrospective study included 63 patients diagnosed with COVID-19 from January 2020 to March 2021. Data on demographic characteristics and clinical characteristics with the levels of IL-6, CRP, and PCT on admission were collected. ROC analysis was performed to determine whether interleukin-6 had a diagnostic value in predicting mortality. IL-6, CRP and procalcitonin values were evaluated by the Spearman correlation analysis. Results: In the ROC analysis performed in terms of predicting mortality, it was observed that IL-6 level predicted mortality at a statistically significant level (area under the curve: 0.708, p=0.004, 95% confidence interval: 0.583-0.833). A value of >358.3 pg/mL for IL-6 showed prognostic significance on mortality. In the Spearman correlation analysis performed between IL-6, CRP and procalcitonin values, a positive correlation was observed between CRP and procalcitonin (r=0.474, p=0.001). Conclusion: The serum levels of IL-6 and CRP can effectively assess disease severity in patients with COVID-19. (English) [ FROM AUTHOR]
{"title":"Evaluation of the Effects of Interleukin-6, C-reactive Protein and Procalcitonin on the Prognosis of the Disease in Patients with COVID-19","authors":"Demet GÜR VURAL, Büşra Usta, Muhammet Samet Emre Daştan, Y. Tanrıverdi Çaycı, K. Bilgin, H. Bilek, A. Birinci","doi":"10.4274/tji.galenos.2022.70298","DOIUrl":"https://doi.org/10.4274/tji.galenos.2022.70298","url":null,"abstract":"Objective: Coronavirus disease-2019 (COVID-19) pandemic caused by the severe acute respiratory syndrome-coronavirus-2 continues across the world. Some patients with COVID-19 develop cytokine storm secondary to virally driven hyper-inflammation. This study aimed to assess the relationship of interleukin-6 (IL-6), procalsitonin (PCT) and C-reactive protein (CRP) levels with the severity of the disease in patients with COVID-19. Materials and Methods: This retrospective study included 63 patients diagnosed with COVID-19 from January 2020 to March 2021. Data on demographic characteristics and clinical characteristics with the levels of IL-6, CRP, and PCT on admission were collected. ROC analysis was performed to determine whether interleukin-6 had a diagnostic value in predicting mortality. IL-6, CRP and procalcitonin values were evaluated by the Spearman correlation analysis. Results: In the ROC analysis performed in terms of predicting mortality, it was observed that IL-6 level predicted mortality at a statistically significant level (area under the curve: 0.708, p=0.004, 95% confidence interval: 0.583-0.833). A value of >358.3 pg/mL for IL-6 showed prognostic significance on mortality. In the Spearman correlation analysis performed between IL-6, CRP and procalcitonin values, a positive correlation was observed between CRP and procalcitonin (r=0.474, p=0.001). Conclusion: The serum levels of IL-6 and CRP can effectively assess disease severity in patients with COVID-19. (English) [ FROM AUTHOR]","PeriodicalId":41088,"journal":{"name":"Turkish Journal of Immunology","volume":"20 1","pages":""},"PeriodicalIF":1.2,"publicationDate":"2022-12-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82537283","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-12-29DOI: 10.4274/tji.galenos.2022.25238
M. Bilgin, Eşe Başbulut, H. S. Baklacioglu, Adem Keskin, Recai Aci
Objective: The effect of severe acute respiratory syndrome-coronavirus-2 (SARS‑CoV‑2) infection on autoimmunity in both disease and post-disease stages has not been fully explained. There is not enough information about the evaluation of autoimmune antibodies in convalescent SARS-CoV-2 patients. This study aimed to investigate the presence and types of autoantibodies in post-illness coronavirus disease-2019 (COVID-19) patients and to compare them with indirect immunofluorescence assay (IIF)-antinuclear antibody (ANA) results before SARS-CoV-2 infection. Materials and Methods: Twenty-four COVID-19 patients with known and reported ANA test results prior to SARS-CoV-2 infection were included in this study. Patients' IIF-ANA, extractable nuclear antigen blot and anti-dsDNA tests were studied three and nine months after SARS-CoV-2 infection. Results: Three months after SARS-CoV-2 infection, 41.66% of patients had a positive IIF-ANA test. When we compared these results with pre-infection ANA results, 3 patients (12.5%) were variable. The first case was chromosomal granular positive before infection and was found to be homogeneous, and cytoplasm was speckled positive after infection. Additionally, Scl-70, DFS70, and anti-dsDNA were found to be positive. We think that lupus symptoms were triggered after COVID-19. The second case had negative ANA before infection, while the ANA was antinuclear membrane positive (2+) three months after infection. Also, anti-RNP/Sm was detected as positive. The third case had negative ANA before infection, and was detected to have speckled weakly positive ANA three months after infection. However, autoantibody positivity was not detected. Conclusion: As a result, these data support the idea that SARS-CoV-2 infection may trigger autoimmunity and be associated with the development of autoantibodies. (English) [ FROM AUTHOR]
{"title":"Could SARS-CoV-2 Trigger the Formation of Antinuclear Antibodies?","authors":"M. Bilgin, Eşe Başbulut, H. S. Baklacioglu, Adem Keskin, Recai Aci","doi":"10.4274/tji.galenos.2022.25238","DOIUrl":"https://doi.org/10.4274/tji.galenos.2022.25238","url":null,"abstract":"Objective: The effect of severe acute respiratory syndrome-coronavirus-2 (SARS‑CoV‑2) infection on autoimmunity in both disease and post-disease stages has not been fully explained. There is not enough information about the evaluation of autoimmune antibodies in convalescent SARS-CoV-2 patients. This study aimed to investigate the presence and types of autoantibodies in post-illness coronavirus disease-2019 (COVID-19) patients and to compare them with indirect immunofluorescence assay (IIF)-antinuclear antibody (ANA) results before SARS-CoV-2 infection. Materials and Methods: Twenty-four COVID-19 patients with known and reported ANA test results prior to SARS-CoV-2 infection were included in this study. Patients' IIF-ANA, extractable nuclear antigen blot and anti-dsDNA tests were studied three and nine months after SARS-CoV-2 infection. Results: Three months after SARS-CoV-2 infection, 41.66% of patients had a positive IIF-ANA test. When we compared these results with pre-infection ANA results, 3 patients (12.5%) were variable. The first case was chromosomal granular positive before infection and was found to be homogeneous, and cytoplasm was speckled positive after infection. Additionally, Scl-70, DFS70, and anti-dsDNA were found to be positive. We think that lupus symptoms were triggered after COVID-19. The second case had negative ANA before infection, while the ANA was antinuclear membrane positive (2+) three months after infection. Also, anti-RNP/Sm was detected as positive. The third case had negative ANA before infection, and was detected to have speckled weakly positive ANA three months after infection. However, autoantibody positivity was not detected. Conclusion: As a result, these data support the idea that SARS-CoV-2 infection may trigger autoimmunity and be associated with the development of autoantibodies. (English) [ FROM AUTHOR]","PeriodicalId":41088,"journal":{"name":"Turkish Journal of Immunology","volume":"14 1","pages":""},"PeriodicalIF":1.2,"publicationDate":"2022-12-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80120029","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-08-16DOI: 10.4274/tji.galenos.2022.18209
B. Aru, Gizem Gürel, G. Yanikkaya Demirel
{"title":"Mesenchymal Stem Cells: History, Characteristics and an Overview of Their Therapeutic Administration","authors":"B. Aru, Gizem Gürel, G. Yanikkaya Demirel","doi":"10.4274/tji.galenos.2022.18209","DOIUrl":"https://doi.org/10.4274/tji.galenos.2022.18209","url":null,"abstract":"","PeriodicalId":41088,"journal":{"name":"Turkish Journal of Immunology","volume":"63 4","pages":""},"PeriodicalIF":1.2,"publicationDate":"2022-08-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"72538856","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-08-16DOI: 10.4274/tji.galenos.2022.26349
Abubaker H. Ali, A. Zidan
Objective: Coronavirus disease-2019 (COVID-19) is a potentially fatal respiratory disease caused by SARS-CoV-2, which has occurred in a human pandemic. This study aims to assess the responses of IgM and IgG antibodies to the virus after 7-14 days following the onset of illness. Materials and Methods: A total of 95 cases, including 67 patients with COVID-19 (24 male and 43 female) and 28 healthy individuals without COVID-19 as the control group (7 male and 21 female), were selected in the present study. IgM and IgG antibodies for COVID-19 were evaluated using rapid chromatographic immunoassay (RCI). Results: RCI demonstrated that IgM antibody was found as positive in 67 patients (100%) after 7-14 days, whereas IgG antibody was found as positive in 56 patients (83.6%) after 7 days and 67 patients (100%) were positive after 14 days. Conclusion: According to the obtained results, RCI for IgM and IgG antibodies can be used to make a quick and accurate diagnosis of COVID-19 infections (English) [ FROM AUTHOR] Amaç: Koronavirüs hastalığı-2019 (COVID-19), bir insan pandemisi olarak ortaya çıkan, SARS-CoV-2 tarafından bulaşan, potansiyel olarak ölümcül bir solunum yolu hastalığıdır. Bu çalışma, hastalığın başlangıcından 7-14 gün sonra IgM ve IgG antikorlarının virüse karşı oluşan antikorları saptamayı amaçlamaktadır. Gereç ve Yöntem: Bu çalışmada COVID-19'lu 67 hasta (24 erkek ve 43 kadın) ve COVID-19'suz 28 sağlıklı birey (7 erkek ve 21 kadın) içeren kontrol grubu olarak olmak üzere toplam 95 olgu irdelendi. COVID-19 için IgM ve IgG antikorları, hızlı kromatografik immünoassay test (RCI) kullanılarak değerlendirildi. Bulgular: RCI ile 7-14 gün sonra 67 hastada (%100) IgM antikoru pozitif, 7 gün sonra 56 hastada (%83.6), 14 gün sonra 67 hastada (%100) IgG antikor pozitifliği saptandı. Sonuç: Elde edilen sonuçlara göre, RCI, IgM ve IgG antikorlarını değerlendirerek, COVID-19 enfeksiyonun hızlı ve doğru teşhisini sağlamak için kullanılabilir (Turkish) [ FROM AUTHOR] Copyright of Turkish Journal of Immunology is the property of Galenos Yayinevi Tic. LTD. STI and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full . (Copyright applies to all s.)
目的:冠状病毒病-2019 (COVID-19)是由SARS-CoV-2引起的一种可能致命的呼吸道疾病，已在人类大流行中发生。本研究旨在评估发病后7-14天IgM和IgG抗体对病毒的反应。材料与方法:本研究共95例，其中新冠肺炎患者67例(男24例，女43例)，未感染新冠肺炎的健康人28例(男7例，女21例)作为对照组。采用快速免疫层析法(RCI)检测COVID-19的IgM和IgG抗体。结果:RCI显示，7 ~ 14 d后IgM抗体阳性67例(100%)，7 d后IgG抗体阳性56例(83.6%)，14 d后阳性67例(100%)。结论:根据所得结果，IgM和IgG抗体的RCI可用于快速准确诊断COVID-19感染(英文)[FROM AUTHOR] Amaç: koronavir hastalığı-2019 (COVID-19)， bir insan pandemisi olarak ortaya çıkan, SARS-CoV-2 tarafından bula an, potansiyel olarak ölümcül bir solunum yolu hastalığıdır。Bu çalışma, hastalığın başlangıcından 7-14 g n sonra IgM ve IgG antikorlarının vir se kar olu an antikorlarka saptamayyi amaçlamaktadır。Gereç ve Yöntem: Bu çalışmada COVID-19' lu67 hasta (24 erkek ve 43 kadın) ve COVID-19'suz 28 sağlıklı birey (7 erkek ve 21 kadın) 控制组olarak olmak zere toplam 95 olgu irdelendi。COVID-19 - IgM - ve - IgG antikorlari, hızlı kromatografik免疫检测(RCI) kullanılarak değerlendirildi。结果:RCI 7-14 g n sonra 67 hasada (%100) IgM antikoru pozitif, 7 g n sonra 56 hasada (%83.6)， 14 g n sonra 67 hasada (%100) IgG antikor pozitifliği saptandir。Sonuç: Elde edilen sonulara göre, RCI, IgM ve IgG antikorlarını değerlendirerek, COVID-19 enfeksiyonun hızlı ve doğru tehisini sağlamak iin kullanılabilir(土耳其语)[来自作者]版权归土耳其免疫学杂志所有，属于Galenos Yayinevi Tic。有限公司未经版权所有者的明确书面许可，STI及其内容不得复制或通过电子邮件发送到多个网站或发布到listserv。但是，用户可以打印、下载或通过电子邮件发送文章供个人使用。这可以删节。对副本的准确性不作任何保证。用户应参阅原始出版版本的材料的完整。(版权适用于所有人。)
{"title":"Detection of Antibodies in Patients with COVID-19 by Rapid Chromatographic Immunoassay","authors":"Abubaker H. Ali, A. Zidan","doi":"10.4274/tji.galenos.2022.26349","DOIUrl":"https://doi.org/10.4274/tji.galenos.2022.26349","url":null,"abstract":"Objective: Coronavirus disease-2019 (COVID-19) is a potentially fatal respiratory disease caused by SARS-CoV-2, which has occurred in a human pandemic. This study aims to assess the responses of IgM and IgG antibodies to the virus after 7-14 days following the onset of illness. Materials and Methods: A total of 95 cases, including 67 patients with COVID-19 (24 male and 43 female) and 28 healthy individuals without COVID-19 as the control group (7 male and 21 female), were selected in the present study. IgM and IgG antibodies for COVID-19 were evaluated using rapid chromatographic immunoassay (RCI). Results: RCI demonstrated that IgM antibody was found as positive in 67 patients (100%) after 7-14 days, whereas IgG antibody was found as positive in 56 patients (83.6%) after 7 days and 67 patients (100%) were positive after 14 days. Conclusion: According to the obtained results, RCI for IgM and IgG antibodies can be used to make a quick and accurate diagnosis of COVID-19 infections (English) [ FROM AUTHOR] Amaç: Koronavirüs hastalığı-2019 (COVID-19), bir insan pandemisi olarak ortaya çıkan, SARS-CoV-2 tarafından bulaşan, potansiyel olarak ölümcül bir solunum yolu hastalığıdır. Bu çalışma, hastalığın başlangıcından 7-14 gün sonra IgM ve IgG antikorlarının virüse karşı oluşan antikorları saptamayı amaçlamaktadır. Gereç ve Yöntem: Bu çalışmada COVID-19'lu 67 hasta (24 erkek ve 43 kadın) ve COVID-19'suz 28 sağlıklı birey (7 erkek ve 21 kadın) içeren kontrol grubu olarak olmak üzere toplam 95 olgu irdelendi. COVID-19 için IgM ve IgG antikorları, hızlı kromatografik immünoassay test (RCI) kullanılarak değerlendirildi. Bulgular: RCI ile 7-14 gün sonra 67 hastada (%100) IgM antikoru pozitif, 7 gün sonra 56 hastada (%83.6), 14 gün sonra 67 hastada (%100) IgG antikor pozitifliği saptandı. Sonuç: Elde edilen sonuçlara göre, RCI, IgM ve IgG antikorlarını değerlendirerek, COVID-19 enfeksiyonun hızlı ve doğru teşhisini sağlamak için kullanılabilir (Turkish) [ FROM AUTHOR] Copyright of Turkish Journal of Immunology is the property of Galenos Yayinevi Tic. LTD. STI and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full . (Copyright applies to all s.)","PeriodicalId":41088,"journal":{"name":"Turkish Journal of Immunology","volume":"79 1","pages":""},"PeriodicalIF":1.2,"publicationDate":"2022-08-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78245032","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-08-16DOI: 10.4274/tji.galenos.2022.08370
Rowen Govender, N. Govender, T. Naicker
{"title":"Does Complement Factor I Correlate with Complement Component 4b in HIV Infected Patients with Preeclampsia?","authors":"Rowen Govender, N. Govender, T. Naicker","doi":"10.4274/tji.galenos.2022.08370","DOIUrl":"https://doi.org/10.4274/tji.galenos.2022.08370","url":null,"abstract":"","PeriodicalId":41088,"journal":{"name":"Turkish Journal of Immunology","volume":"65 1","pages":""},"PeriodicalIF":1.2,"publicationDate":"2022-08-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75046913","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：